Brown Advisory Inc. Trims Stake in Phreesia, Inc. (NYSE:PHR)

Brown Advisory Inc. lowered its stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 32.6% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 3,770,480 shares of the company's stock after selling 1,824,110 shares during the period. Brown Advisory Inc. owned approximately 6.42% of Phreesia worth $96,373,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in PHR. Johnson Financial Group Inc. boosted its stake in Phreesia by 381.3% during the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock valued at $28,000 after purchasing an additional 896 shares during the last quarter. Quarry LP boosted its stake in shares of Phreesia by 210.9% in the 4th quarter. Quarry LP now owns 2,835 shares of the company's stock worth $71,000 after buying an additional 1,923 shares during the last quarter. KBC Group NV purchased a new position in shares of Phreesia in the 1st quarter worth approximately $74,000. NewEdge Advisors LLC boosted its stake in shares of Phreesia by 12.1% in the 4th quarter. NewEdge Advisors LLC now owns 4,256 shares of the company's stock worth $107,000 after buying an additional 459 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Phreesia by 1,023.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,660 shares of the company's stock worth $142,000 after buying an additional 5,156 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

Wall Street Analysts Forecast Growth

PHR has been the topic of a number of research analyst reports. Wall Street Zen upgraded Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Truist Financial boosted their target price on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, May 29th. Canaccord Genuity Group cut their target price on Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a research note on Thursday, May 29th. Citigroup restated a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. Finally, DA Davidson cut their target price on Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia presently has a consensus rating of "Buy" and an average target price of $31.64.

Phreesia Stock Performance

Shares of NYSE:PHR traded down $1.93 during mid-day trading on Friday, reaching $26.74. The company had a trading volume of 504,545 shares, compared to its average volume of 456,712. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -36.13 and a beta of 0.72. The company's 50-day moving average price is $26.34 and its 200-day moving average price is $26.36. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53.

Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The business had revenue of $115.94 million for the quarter, compared to analysts' expectations of $115.00 million. During the same quarter in the previous year, the firm posted ($0.05) EPS. The business's revenue for the quarter was up 14.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 1,213 shares of the business's stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $23.81, for a total transaction of $28,881.53. Following the sale, the general counsel owned 137,921 shares of the company's stock, valued at $3,283,899.01. The trade was a 0.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of the business's stock in a transaction on Thursday, June 26th. The shares were sold at an average price of $27.67, for a total transaction of $77,531.34. Following the sale, the director directly owned 22,037 shares in the company, valued at $609,763.79. The trade was a 11.28% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,781 shares of company stock worth $1,504,911. Company insiders own 5.50% of the company's stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.